{"id":"W2588436059","doi":"10.1093/annonc/mdw372.52","title":"ATLAS: A phase 3 trial evaluating the efficacy of apalutamide (ARN-509) in patients with high-risk localized or locally advanced prostate cancer receiving primary radiation therapy","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Prostate cancer; Clinical endpoint; Enzalutamide; Oncology; Internal medicine; Androgen deprivation therapy; Urology; Placebo; Radiation therapy; Randomized controlled trial; Cancer; Androgen receptor; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009394519,0.00119184,0.001775415,0.0004185458,0.00032709,0.001028285,0.0009563486,0.0009520081,0.006326499],"category_scores_gemma":[0.0009637127,0.0004281862,0.001290866,0.0004846342,0.001073911,0.0009012256,0.0004129101,0.002942278,0.001192498],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008811246,"about_ca_system_score_gemma":0.001488646,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001800078,"about_ca_topic_score_gemma":0.005641427,"domain_scores_codex":[0.9996716,0.0001774975,0.00001170093,0.00004972907,0.00003356949,0.00005586255],"domain_scores_gemma":[0.9994897,0.0001154996,0.00009433395,0.00004031145,0.00002415823,0.0002359823],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8345763,0.01536705,0.004798691,0.001081516,0.002544931,0.0002852864,0.000207984,0.004911599,0.02731832,0.001037783,0.01192424,0.09594627],"study_design_scores_gemma":[0.7995667,0.1760297,0.01073021,0.00004704885,0.0009838429,0.0004167361,0.00009557091,0.002931609,0.00281396,0.0008263589,0.00549153,0.00006675909],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9844599,0.002807152,0.000814361,0.001153103,0.0003386558,0.001165349,0.003084151,0.0004308315,0.005746436],"genre_scores_gemma":[0.9835272,0.002359022,0.002117922,0.001411965,0.0003128786,0.001152315,0.004752418,0.00008571197,0.004280552],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006326499,"threshold_uncertainty_score":0.02116424,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07262357971532579,"score_gpt":0.4403411784910806,"score_spread":0.3677175987757548,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}